APA (7th ed.) Citation

S, S., JE, M., E, M., & P, V. (2025). Ongoing phase 2 agents for multiple sclerosis: Could we break the phase 3 trial deadlock? Expert opinion on investigational drugs, 34(3), 217. https://doi.org/10.1080/13543784.2025.2472240

Chicago Style (17th ed.) Citation

S, Susin-Calle, Martinez-Rodriguez JE, Munteis E, and Villoslada P. "Ongoing Phase 2 Agents for Multiple Sclerosis: Could We Break the Phase 3 Trial Deadlock?" Expert Opinion on Investigational Drugs 34, no. 3 (2025): 217. https://doi.org/10.1080/13543784.2025.2472240.

MLA (9th ed.) Citation

S, Susin-Calle, et al. "Ongoing Phase 2 Agents for Multiple Sclerosis: Could We Break the Phase 3 Trial Deadlock?" Expert Opinion on Investigational Drugs, vol. 34, no. 3, 2025, p. 217, https://doi.org/10.1080/13543784.2025.2472240.